Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2026-05-13 Report Publication Anno…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Filing on Interim Management Report as at March 31st 2026
Report Publication Announcement Classification · 84% confidence The text is a press release stating that the company has filed and made available its Interim Management Report as at March 31, 2026. It contains no substantive financial statements or analysis itself, only an announcement that the report is available (‘Vedi allegato’). Under the “menu vs meal” rule, this is an announcement of a report publication rather than the report itself. Therefore, it should be classified as a Report Publication Announcement (RPA).
2026-05-13 Italian
Interim Management Report as at March 31st 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “INTERIM MANAGEMENT REPORT” as at March 31, 2026 and includes detailed consolidated financial statements (balance sheet, income statement, cash flow), explanatory notes, management discussion of financial performance and significant events after the period. It is a comprehensive quarterly report containing actual financial data rather than merely announcing or certifying a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-13 English
Resoconto Intermedio di Gestione al 31 marzo 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Resoconto Intermedio di Gestione al 31 Marzo 2026” (Interim Management Report) for PharmaNutra S.p.A. It includes consolidated financial statements (income statement, balance sheet, cash flow), commentary on business segments, key metrics for the first quarter of 2026, and post-period events. It is a comprehensive financial report for a period shorter than a full fiscal year, containing substantive financial data, and thus fits the definition of an Interim/Quarterly Report. Q1 2026
2026-05-13 Italian
Q1 2026 Results Presentation
Investor Presentation Classification · 96% confidence The document is a slide‐style deck prepared “for use during meetings with investors and financial analysts,” featuring bullet highlights, charts, forward‐looking disclaimers, and Q1 2026 P&L, balance sheet and cash flow data in presentation format. It is not the statutory quarterly report itself but a narrated investor presentation. Therefore, it should be classified as Investor Presentation (IP).
2026-05-11 English
IL CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 31 MARZO 2026
Interim / Quarterly Report Classification · 91% confidence The document is the full interim management report (‘Resoconto Intermedio di Gestione’) at March 31, 2026, containing detailed financial tables (income, cash flow, balance sheet), management commentary, outlook and statutory attestations. It is not merely an announcement of publication; it is the actual interim/quarterly financial report. Therefore it corresponds to an Interim / Quarterly Report (IR). Q1 2026
2026-05-11 Italian
THE BoD APPROVES THE INTERIM MANAGEMENT REPORT AS OF MARCH 31ST 2026
Interim / Quarterly Report Classification · 90% confidence The document is a press release titled “THE BoD APPROVES THE INTERIM MANAGEMENT REPORT AS OF MARCH 31ST 2026” and contains extensive unaudited Q1 2026 financial statements (balance sheet, income statement, cash flow), detailed segment analyses, commentary on results and outlook, and a certification pursuant to Article 154-bis. It is not merely an earnings summary nor a simple announcement of publication, but a full interim/quarterly management report with substantive financial data. Therefore it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.